Italiano and colleagues assess the efficacy and safety of treatment of gastroenteropancreatic neuroendocrine neoplasms with regorafenib plus avelumab and explore biomarkers with resistance prediction value, such as programmed death 1 and indoleamine 2,3-dioxygenase 1 expression and activity.
- Sophie Cousin
- Jean-Philippe Guégan
- Antoine Italiano
